Evidence map›Paper›PMID 31703080›Full record

ArticlePloS one2019

Direct cost of health care for individuals with community associated Clostridium difficile infections: A population-based cohort study.

Harminder Singh, Zoann Nugent, A Walkty, B Nancy Yu, Lisa M Lix, Laura E Targownik, Charles N Bernstein, Julia Witt

Abstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Association of antimicrobial consumption withInfection prevention in practice · 2025
    Article
  3. Article
  4. Approaching pathogenicbioRxiv : the preprint server for biology · 2024
    Article
  5. Fidaxomicin to prevent recurrentJAC-antimicrobial resistance · 2023
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Harminder SinghUniversity of Manitoba IBD Clinical and Research Center, Winnipeg, Manitoba, Canada.ORCID 0000-0002-9354-2356
Zoann NugentUniversity of Manitoba IBD Clinical and Research Center, Winnipeg, Manitoba, Canada.
A WalktyDepartment of Internal Medicine, University of Manitoba, Max Rady College of Medicine, Winnipeg, Manitoba, Canada.
B Nancy YuDepartment of Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
Lisa M LixDepartment of Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
Laura E TargownikUniversity of Manitoba IBD Clinical and Research Center, Winnipeg, Manitoba, Canada.
Charles N BernsteinUniversity of Manitoba IBD Clinical and Research Center, Winnipeg, Manitoba, Canada.
Julia WittDepartment of Economics, University of Manitoba, Winnipeg, Manitoba, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEven though the incidence of community-acquired Clostridium difficile infection (CDI) is reported to be increasing, few studies have reported on the healthcare costs of community-acquired CDI. We estimated cost of care for individuals with community-associated CDI and compared with that for matched controls without CDI in the time period of six months before to one year after CDI.

methodsAll individuals in the province of Manitoba, diagnosed with CDI between July 2005 and March 2015 were matched up to 4 individuals without CDI. Health care utilization and direct costs resulting from hospitalizations, physician reimbursement claims and prescriptions were determined from the population based provincial databases. Quantile regressions were performed to determine predictors of cost of individuals with community associated CDI.

resultsOf all CDIs, 30-40% in each period of the study had community-associated CDI; of which 12% were recurrent CDIs. The incremental median and 90th percentile cost of care for individuals with community-associated CDI was $800 and $16,000 respectively in the six months after CDI diagnosis. After adjustment for age, co-morbidities, sex, socioeconomic status and magnitude of health care utilization prior to CDI, the median incremental cost for recurrent CDI was $1,812 and that for a subsequent episode of CDI was $3,139 compared to those with a single community-associated CDI episode. The median cost for a prescription of Vancomycin was $316 (IQR 209-489).

conclusionsHealth care costs of an episode of community-associated CDI have been much more than the cost of antibiotic treatment. Our study provides population-based data for formal cost effectiveness analysis for use of newer treatments for community-associated CDI.

Indexed as

Health Care CostsAdultAgedCase-Control StudiesClostridium InfectionsCohort StudiesCommunity-Acquired InfectionsFemaleFollow-Up StudiesHumansMaleMiddle AgedMultivariate AnalysisRegression Analysis

Identifiers

PMID31703080
PMCPMC6839863

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.